08:21 AM EDT, 03/17/2026 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) said Tuesday data from its ongoing trial evaluating EP-104GI for eosinophilic esophagitis treatment showed 59% of patients achieved clinical remission at 12 weeks.

At 24 weeks, 76% of the patients maintained clinical remission, Eupraxia said.

No serious adverse events have been reported, and the drug continues to be well tolerated at all dose levels by patients, the company said.

Eupraxia said that top-line data from the phase 2b portion of the trial is expected in Q3.